A small-molecule PRCP inhibitor blocked IGF1R/HER3 signaling in breast cancer cells, and enhanced the responsiveness of human ER+ breast cancer tumors in mice to endoxifen, an active metabolite of TAM. Here, ESR1 is linked to breast carcinoma.